Published in Clin J Am Soc Nephrol on November 01, 2008
The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis (OPPORTUNITY) | NCT00503698
Prevalence and correlates of fatigue in chronic kidney disease and end-stage renal disease: are sleep disorders a key to understanding fatigue? Am J Nephrol (2013) 0.94
New insights into the role of anabolic interventions in dialysis patients with protein energy wasting. Curr Opin Nephrol Hypertens (2009) 0.82
The Diet and Haemodialysis Dyad: Three Eras, Four Open Questions and Four Paradoxes. A Narrative Review, Towards a Personalized, Patient-Centered Approach. Nutrients (2017) 0.75
Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med (1999) 4.63
Association of morbid obesity and weight change over time with cardiovascular survival in hemodialysis population. Am J Kidney Dis (2005) 2.47
Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol (2000) 2.47
Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab (1998) 2.17
Revisiting mortality predictability of serum albumin in the dialysis population: time dependency, longitudinal changes and population-attributable fraction. Nephrol Dial Transplant (2005) 2.16
Appetite and inflammation, nutrition, anemia, and clinical outcome in hemodialysis patients. Am J Clin Nutr (2004) 1.75
Comparing outcome predictability of markers of malnutrition-inflammation complex syndrome in haemodialysis patients. Nephrol Dial Transplant (2004) 1.71
Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res (2008) 1.49
GH, GH receptor, GH secretagogue receptor, and ghrelin expression in human T cells, B cells, and neutrophils. J Clin Endocrinol Metab (2001) 1.35
Factors associated with health-related quality of life among hemodialysis patients in the DOPPS. Qual Life Res (2007) 1.35
Activation of the prolactin receptor but not the growth hormone receptor is important for induction of mammary tumors in transgenic mice. J Clin Invest (1997) 1.31
Increased prevalence of colonic polyps and altered lymphocyte subset pattern in the colonic lamina propria in acromegaly. Clin Endocrinol (Oxf) (1997) 1.25
Increased survival after major thermal injury: the effect of growth hormone therapy in adults. J Trauma (1995) 1.19
Does the GH-IGF axis play a role in cancer pathogenesis? Growth Horm IGF Res (2000) 1.14
Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab (1993) 1.09
The IGF axis in the prostate. Horm Metab Res (1994) 1.08
Additive effects of cortisol and growth hormone on regional and systemic lipolysis in humans. Am J Physiol Endocrinol Metab (2003) 1.07
Impaired actions of insulin-like growth factor 1 on protein Synthesis and degradation in skeletal muscle of rats with chronic renal failure. Evidence for a postreceptor defect. J Clin Invest (1996) 1.06
The metabolic role of growth hormone in humans with particular reference to fasting. Growth Horm IGF Res (2005) 1.04
Growth hormone treatment during hemodialysis in a randomized trial improves nutrition, quality of life, and cardiovascular risk. J Am Soc Nephrol (2007) 1.00
Impaired JAK-STAT signal transduction contributes to growth hormone resistance in chronic uremia. J Clin Invest (2001) 0.98
Effects of growth hormone on lipid metabolism in humans. Growth Horm IGF Res (2003) 0.96
Placebo-controlled, double-blind, cross-over trial of growth hormone treatment in prepubertal children with chronic renal failure. Lancet (1991) 0.92
Effects of treatment with recombinant human growth hormone on insulin sensitivity and glucose metabolism in adults with growth hormone deficiency. Metabolism (1993) 0.90
Long-term treatment of growth retarded children with chronic renal insufficiency, with recombinant human growth hormone. Kidney Int (1996) 0.89
Differential effects of growth hormone therapy in malnourished hemodialysis patients. Kidney Int (2001) 0.86
Double-blind, placebo-controlled study of growth hormone treatment in elderly patients undergoing chronic hemodialysis: anabolic effect and functional improvement. Am J Kidney Dis (1999) 0.86
Recombinant human growth hormone therapy in malnourished dialysis patients: a randomized controlled study. Am J Kidney Dis (1998) 0.86
Growth hormone replacement is important for the restoration of parathyroid hormone sensitivity and improvement in bone metabolism in older adult growth hormone-deficient patients. J Clin Endocrinol Metab (2005) 0.85
Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study. Clin Nephrol (2000) 0.85
Expression of insulin-like growth factor-1 in uremic rats: growth hormone resistance and nutritional intake. Kidney Int (1993) 0.84
Cardiovascular effects of growth hormone treatment in growth-hormone-deficient adults: stimulation of the renin-aldosterone system. Clin Sci (Lond) (1991) 0.84
Recombinant human growth hormone improves muscle amino acid uptake and whole-body protein metabolism in chronic hemodialysis patients. Am J Clin Nutr (2005) 0.84
Growth hormone treatment and cancer risk. Endocrinol Metab Clin North Am (2007) 0.82
Growth hormone treatment in hemodialysis patients--a randomized, double-blind, placebo-controlled study. Scand J Urol Nephrol (2004) 0.81
Effects of recombinant human growth hormone on muscle protein turnover in malnourished hemodialysis patients. J Clin Invest (1997) 0.81
Effects of human growth hormone in critically ill nonseptic patients: results from a prospective, randomized, placebo-controlled trial. Crit Care Med (1995) 0.81
Growth hormone and fluid retention. Horm Res (1999) 0.80
PTH circadian rhythm and PTH target-organ sensitivity is altered in patients with adult growth hormone deficiency with low BMD. J Bone Miner Res (2007) 0.80
Effects of recombinant human growth hormone in adults receiving maintenance hemodialysis. J Am Soc Nephrol (1991) 0.80
Effect of insulin-like growth factor binding proteins on the response of proximal tubular cells to insulin-like growth factor-I. Kidney Int (1997) 0.79
Recombinant growth hormone use pretransplant and risk for post-transplant lymphoproliferative disease--a report of the NAPRTCS. Pediatr Transplant (2007) 0.79
The effects of recombinant human growth hormone and intradialytic parenteral nutrition in malnourished hemodialysis patients. Am J Kidney Dis (1993) 0.79
Changes in cardiac muscle mass and function in hemodialysis patients during growth hormone treatment. Clin Nephrol (2000) 0.79
Growth hormone, insulin-like growth factors and their binding proteins in adult hemodialysis patients treated with recombinant human growth hormone. Clin Nephrol (1999) 0.78
Stimulation of erythropoietin secretion by continuous subcutaneous infusion of recombinant human GH in anemic patients with chronic renal failure. Eur J Endocrinol (1998) 0.78
Effects of growth hormone on the differentiation of mouse B-lymphoid precursors. J Pharmacol Sci (2005) 0.78
Short-term effects of recombinant human growth hormone in CAPD patients. Kidney Int (1994) 0.78
Confidence intervals following group sequential tests in clinical trials. Biometrics (1987) 0.77
Growth hormone effects on protein metabolism. Endocrinol Metab Clin North Am (2007) 0.77
Effects of short-term recombinant human growth hormone therapy on plasma leptin concentrations in dialysis patients. Nephrol Dial Transplant (2002) 0.77
Reduced food intake is the main cause of low growth hormone receptor expression in uremic rats. Mol Cell Endocrinol (1994) 0.77
Is there an association between neoplasia and primary or secondary hyperparathyroidism? Am J Nephrol (1988) 0.76
Growth hormone induces anabolism in malnourished maintenance haemodialysis patients. Nephrol Dial Transplant (2005) 0.76
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med (2015) 18.66
Obesity and diabetes in the developing world--a growing challenge. N Engl J Med (2007) 10.54
Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med (2002) 10.52
The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int (2010) 9.25
Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med (2013) 7.54
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA (2008) 7.50
Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J (2004) 7.02
Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest (2003) 6.30
Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int (2004) 6.04
Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med (2010) 5.50
Cachexia: a new definition. Clin Nutr (2008) 5.49
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. Kidney Int (2009) 4.72
The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol (2011) 4.57
Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int (2004) 4.51
The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int (2002) 4.29
Protein degradation by the ubiquitin-proteasome pathway in normal and disease states. J Am Soc Nephrol (2006) 4.01
Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis (2003) 3.90
Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation (2004) 3.78
Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation (2004) 3.71
Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet (2003) 3.70
Effect of dipyridamole plus aspirin on hemodialysis graft patency. N Engl J Med (2009) 3.69
Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int (2003) 3.54
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol (2011) 3.52
EBPG on Vascular Access. Nephrol Dial Transplant (2007) 3.26
Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions. J Clin Invest (2004) 2.98
Estimating baseline kidney function in hospitalized patients with impaired kidney function. Clin J Am Soc Nephrol (2012) 2.94
Hemodialysis. N Engl J Med (2010) 2.89
Non-infected hemodialysis catheters are associated with increased inflammation compared to arteriovenous fistulas. Kidney Int (2009) 2.89
Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int (2004) 2.81
Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol (2009) 2.77
Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies. J Clin Oncol (2011) 2.76
Hemodialysis vascular access dysfunction: a cellular and molecular viewpoint. J Am Soc Nephrol (2006) 2.74
EBPG guideline on nutrition. Nephrol Dial Transplant (2007) 2.68
Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant (2010) 2.64
Insulin resistance accelerates muscle protein degradation: Activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology (2006) 2.62
Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab (2008) 2.60
Early intervention improves mortality and hospitalization rates in incident hemodialysis patients: RightStart program. Clin J Am Soc Nephrol (2007) 2.60
Timing of initiation of dialysis in critically ill patients with acute kidney injury. Clin J Am Soc Nephrol (2006) 2.56
Commonly used surrogates for baseline renal function affect the classification and prognosis of acute kidney injury. Kidney Int (2009) 2.53
Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int (2004) 2.52
Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. Crit Care (2010) 2.51
Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab (2007) 2.51
Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med (2012) 2.51
The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int (2003) 2.43
Vitamin D reduces left atrial volume in patients with left ventricular hypertrophy and chronic kidney disease. Am Heart J (2012) 2.42
Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol (2006) 2.37
Biological markers of acute kidney injury. J Am Soc Nephrol (2011) 2.36
Relationships among inflammation nutrition and physiologic mechanisms establishing albumin levels in hemodialysis patients. Kidney Int (2002) 2.27
Association between physical performance and all-cause mortality in CKD. J Am Soc Nephrol (2013) 2.26
Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting. J Clin Invest (2005) 2.24
Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation (2003) 2.22
The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant (2005) 2.21
Dysfunctional high-density lipoprotein in patients on chronic hemodialysis. J Am Coll Cardiol (2012) 2.21
Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase. J Am Soc Nephrol (2004) 2.13
Expert opinion on temporary treatment recommendations for Fabry disease during the shortage of enzyme replacement therapy (ERT). Mol Genet Metab (2010) 2.13
Podocyte number in normotensive type 1 diabetic patients with albuminuria. Diabetes (2002) 2.12
Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant (2003) 2.10
Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. Kidney Int (2013) 2.08
Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation (2009) 2.07
Low health literacy associates with increased mortality in ESRD. J Am Soc Nephrol (2010) 2.03
Predicting mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry. Am J Kidney Dis (2011) 2.01
Sepsis as a cause and consequence of acute kidney injury: Program to Improve Care in Acute Renal Disease. Intensive Care Med (2010) 2.00
Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab (2003) 1.93
Relationship between volume status and blood pressure during chronic hemodialysis. Kidney Int (2002) 1.93
Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int (2012) 1.92
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology. Clin J Am Soc Nephrol (2012) 1.90
EBPG guideline on dialysis strategies. Nephrol Dial Transplant (2007) 1.90
Association of dialysate bicarbonate concentration with mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis (2013) 1.90
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol (2009) 1.88
The associations between race and geographic area and quality-of-care indicators in patients approaching ESRD. Clin J Am Soc Nephrol (2013) 1.87
Fabry disease: guidelines for the evaluation and management of multi-organ system involvement. Genet Med (2006) 1.87
Associations among perceived and objective disease knowledge and satisfaction with physician communication in patients with chronic kidney disease. Kidney Int (2011) 1.87
Clinical and epidemiological description of aortic dissection in Turner's syndrome. Cardiol Young (2006) 1.86
Etiology of the protein-energy wasting syndrome in chronic kidney disease: a consensus statement from the International Society of Renal Nutrition and Metabolism (ISRNM). J Ren Nutr (2013) 1.85
Linkage of hypoalbuminemia, inflammation, and oxidative stress in patients receiving maintenance hemodialysis therapy. Am J Kidney Dis (2003) 1.83
Balancing Fistula First with Catheters Last. Am J Kidney Dis (2007) 1.83
Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy. J Am Soc Nephrol (2006) 1.82
The precision of estimating protein intake of patients with chronic renal failure. Kidney Int (2002) 1.81
Accelerated lean body mass loss in incident chronic dialysis patients with diabetes mellitus. Kidney Int (2005) 1.80
Satellite cell dysfunction and impaired IGF-1 signaling cause CKD-induced muscle atrophy. J Am Soc Nephrol (2010) 1.77
Obesity and oxidative stress predict AKI after cardiac surgery. J Am Soc Nephrol (2012) 1.77
Weight loss increases circulating levels of ghrelin in human obesity. Clin Endocrinol (Oxf) (2002) 1.76
Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. Kidney Int (2011) 1.74
GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab (2013) 1.74
Impact of timing of initiation of dialysis on mortality. J Am Soc Nephrol (2003) 1.73
Role of the GH/IGF-1 axis in lifespan and healthspan: lessons from animal models. Growth Horm IGF Res (2008) 1.72
Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J (2010) 1.72
Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy. Am J Cardiol (2006) 1.71
The cardiac transcription network modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. PLoS Genet (2011) 1.69
Inflammatory signals associated with hemodialysis. Kidney Int (2002) 1.69
Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet (2012) 1.69
Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet (2011) 1.68